AKBA earnings call for the period ending March 31, 2019.
News & Analysis: Akebia Therapeutics
AKBA earnings call for the period ending December 31, 2018.
Good news on several fronts helped lift many stocks.
Great news from two late-stage studies lit a fire under the biopharmaceutical stock.
Traders cheer after the company completes its merger agreement. Here's what investors need to know.
Shares of both companies tumble after the two entities announced the signing of a merger agreement. Here's what investors need to know.
Akebia Therapeutics gets a sizable equity investment from Vifor Pharma as part of a supply agreement for the experimental anemia drug vadadustat.
An expanded licensing pact with Otsuka boosted investors' optimism.
The development-stage biotech saw investors get skittish, and the reason may be that some of them hadn't done their homework.
Which stock wins in a head-to-head match-up between Organovo and Akebia Therapeutics?